Skip to main content

Table 1 Demographic details for each cohort

From: ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies

  Control PD DLB p value
Sex (M:F) 6:6 7:4 7:4 0.68+
Age (years) 77 ± 10 (62–92) 78 ± 6 (71–88) 78 ± 6 (67–88) 0.94
PMD (hours) 21 ± 11 (6–36) 13 ± 7 (3–23) 24.5 ± 12 (4–39) 0.07
Duration (years) - 19 ± 8 (8–36) 7 ± 4 (1–13) <0.001
Braak PD stage # - 9 IV; 2 V/VI 0 IV; 11 V/VI <0.001+
NIA Regan AD * 0/12 0/11 1/11 0.37+
CDR 0.0 ± 0.1 (0–0.5) 0.1 ± 0.2 (0–0.5) 2.4 ± 0.8 (1–3)# <0.001+
Aβ42 (μg/ml) ^ 13 ±8 (7.4-24.9) 16.5 ± 10 (7.0-31.1) 31.4 ± 11(17.8-42.3) # 0.046
  1. # [1].
  2. * [3] None of the 11 PD cases and only 1 of the 11 DLB cases reached diagnostic criteria for Alzheimer’s disease, with neuritic beta-amyloid plaques and tau-positive neurofibrillary tangles present in this single DLB case. All other DLB cases displayed diffuse beta-amyloid plaques.
  3. ^Data obtained from parahippocampal cortices.
  4. #Different from other groups on posthoc protected t test.
  5. +Chi-square test, Analysis of variance (ANOVA).
  6. Data are presented as mean ± standard deviation (range) for post-mortem delay (PMD), age at death (Age), disease duration (Duration), clinical dementia rating scale (CDR) and β-amyloid 1–42 protein levels (Aβ42).